Regulatory

Apr 10, 2017
By
Nine months on from the 2016 EFPIA Disclosure Code deadline — requiring all member companies to publish data concerning their transfer-of-value transactions to HCPs — EFPIA's Andrew Powrie-Smith offered an update on media and industry responses.
Apr 10, 2017
If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change, writes Peter Muller.
Apr 07, 2017
By
Curing cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump’s administration, writes James Nathanielsz.
Apr 07, 2017
Pharmaceutical Executive
Pilot study affirms the value of a standards-based solution for prescription drug traceability—and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.
Apr 05, 2017
By
Scott Gottlieb answers Senators' questions at his confirmation hearing before the Senate Health, Education, Labor and Pensions Committee.
Apr 05, 2017
Amidst hundreds of presentations on new developments in cancer research and treatment discovery at the AACR meeting this week, FDA policies for speeding promising new therapies to patients garnered a good deal of attention.
Apr 04, 2017
Even though uncertainty still exists with Trump’s presidency, current laws will remain intact for the time being. That’s why having a strong compliance strategy in place is the safest bet for all life sciences companies. This article reviews the top of compliance for pharma to be on the look out for.
Mar 28, 2017
By Pharmaceutical Executive Editors
The development of highly effective cures for hepatitis C has prompted a panel of experts to propose an innovative financing arrangement to make these therapies more available to “neglected” populations in the U.S.
Mar 28, 2017
Jill Wechsler outlines how the new FDA commissioner tasked with curbing regulation, speeding approvals—and collecting more fees to do it.
Mar 22, 2017
FDA efforts to speed more new generic drugs to market probably won’t do much to reduce high drug prices, writes Jill Wechsler.
native1_300x100
read more

посмотреть
lorem ipsum